Puffy hands and fingers, as well as other symptoms, can precede the “warning sign” of Raynaud’s syndrome as the initial ...

A new interdisciplinary model for systemic sclerosis integrates imaging, AI, and personalized care to detect cardiac ...

Nearly half of patients with systemic sclerosis report symptoms of disordered eating, according to data published in ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A new study finds nearly 50% of systemic sclerosis patients show signs of ARFID, raising concerns about disordered eating ...

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's ...

Kris Aquino announced Monday she will enter a six-month preventive isolation period as part of her treatment for multiple ...

Adicet Bio doses first systemic sclerosis patient in ADI-001 trial Company News Published 07/24/2025, 07:08 AM 0 ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease. Both trials met the primary endpoint of ...

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic ...

REDWOOD CITY, Calif. & BOSTON, July 24, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...